Citius Oncology, Inc. (CTOR) - Long-Term Debt to Capital

Citius Oncology, Inc. (CTOR) delegates production and testing to third-party contractors, completely excluding its own plants from the business model. Meanwhile, strict oversight of testing protocols ensures the stable development of drugs. The price history on the chart below illustrates the asset's dynamics, where the metric stands at 0.26. The business's success is based on US regulatory approval, a therapeutic advantage over analogs, and the willingness of insurance companies to cover treatment costs.

This indicator assesses financial stability by comparing liabilities with a maturity of over one year against total equity to determine the degree of dependence on external financing. Analysis of long-term debt-to-equity is critical for Citius Oncology, Inc. (CTOR), as a high burn rate in the absence of sales and the complexities of drug certification make the company extremely vulnerable to debt leverage.